What is Anthrax Treatment Market?
Anthrax is a serious infectious illness caused by the microbe Bacillus anthracis, a hardy, spore-forming bacterium that can survive in extreme conditions for a long time. This infection primarily affects livestock and wild game. It spreads through direct or indirect contact with sick animals. It is generally infected by eating contaminated meat or inhaling the spores. The standard treatment used for anthrax is an antibiotic that involves levofloxacin, doxycycline (Vibramycin) or ciprofloxacin (Cipro). The antitoxins are also used in the anthrax treatment such as raxibacumab and obiltoxaximab for inhalation anthrax.
The market study is being classified and major geographies with country level break-up.
Altimmune Inc. (United States), Elusys Therapeutics, Inc. (United States), Emergent BioSolutions, Inc. (United States), Porton Biopharma Limited (United Kingdom), Pfizer Inc. (United States), Bayer AG (Germany), GlaxoSmithKline plc (United Kingdom), Teva Pharmaceutical Industries Ltd (Israel) and Eli Lilly and Company (United States) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anthrax Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Anthrax Treatment market by Type, Application and Region.
On the basis of geography, the market of Anthrax Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Research Funding and the Development of the Novel Therapies
- Growing Threat of Exposure among the Civilian Population and Military Forces
- Increased Research and Development Activities
- Growing Resistance of Microorganisms against Drugs
- Growth in the Healthcare Industry Worldwide
- Increased Research and Development Investments by Major Players
- Stringent Government Rules and Regulations
Market Leaders and some development strategies
In June 2020, Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. Compan's this program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA).
Key Target AudienceAnthrax Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase